Bayer and Lilly make radioligand progress
First-in-human trial initiations feature anti-PSMA radioligands, KRAS G12D, Nectin-4 and more.
Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
A new order in BTK inhibition
Imbruvica faces challenges on multiple fronts.
Point’s big Splash falls short
Crossover hits overall survival, pouring doubts on the group’s deal hopes.
Lilly makes steady progress in non-covalent BTK inhibition
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.
A trio of new pivotal trial entries
AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.
ESMO 2023 – red flags for PSMAfore
The study of Novartis’s Pluvicto in pre-chemo prostate cancer is a bust on overall survival, with questions raised about trial design.
